Cytokinetics, Incorporated (CYTK) - Financial and Strategic SWOT
Analysis Review
Reference Code: GDPH66590FSA Publication Date: MAY 2012
280 East Grand Avenue Phone +1 650 6243000 Revenue 4 (million USD)
South San Francisco, CA Fax +1 650 6243010 Net Profit -47.86 (million USD)
94080 Website www.cytokinetics.com Employees 79 (Estimated)
Pharmaceuticals &
United States Exchange CYTK [NASDAQ] Industry
Healthcare
Company Overview
Cytokinetics, Incorporated (Cytokinetics) is a clinical stage biopharmaceutical company. The company carries out the discovery
and development of innovative small molecule based therapeutics for modulation of muscle function for various diseases and
medical conditions. The company focuses its research and development programs related to the biology of muscle function
modulating the contractility of cardiac, skeletal and smooth muscle. The pipeline portfolio of the company includes omecamtiv
mecarbil (CK-1827452) in intravenous and oral formulations; CK-2017357; CK-2127107; smooth muscle myosin inhibitor protein,
which are in different phases of clinical and non-clinical development.
Key Executives SWOT Analysis
Name Title Cytokinetics, Incorporated, SWOT Analysis
Robert I. Blum Chief Executive Officer Strengths Weaknesses
Stephen Dow Director
Termination of Alliance with
Dr. Denise M. Gilbert, Director Patent Portfolio
GlaxosmithKline
Ph.D. Focused Research Activities
Weak Profitability Indicators
Dr. L. Patrick Gage, Ph.D. Chairman
Santo J. Costa Director
Source: Annual Report, Company Website, Primary and Secondary
Opportunities Threats
Research, GlobalData
Orphan Drug Designation Competitive Landscape
Share Data
Product Pipeline Portfolio Uncertain Research and
Cytokinetics, Incorporated
Development Activities
Share Price (USD) as on 11- 0.93
May-2012
Source: Annual Report, Company Website, Primary and Secondary Research,
EPS (USD) -0.72 GlobalData
Market Cap (million USD) 74
Enterprise Value (million USD) 55
Shares Outstanding (million) 78
Source: Annual Report, Company Website, Primary and Secondary
Research, GlobalData
Financial Performance Recent Developments
Apr 26, 2012 Cytokinetics Reports Revenue Of $1.8m In Q1
2012
Mar 07, 2012 Cytokinetics Announces Board Changes
Feb 02, 2012 Cytokinetics Reports Q4 2011 Results
Oct 27, 2011 Cytokinetics Reports Revenue Of $1.43m In
Q3 2011
Source: Annual Report, Company Website, Primary and Secondary Research,
GlobalData
Source: Annual Report, Company Website, Primary and Secondary
Research, GlobalData
Cytokinetics, Incorporated (CYTK) - Financial and Strategic SWOT Reference Code: GDPH66590FSA
Analysis Review
Source : www.globalcompanyintelligence.com Page 1
© GlobalData. This report is a licensed product and is not to be copied, reproduced, shared or resold in any form
Table of Contents
Table of Contents ............................................................................................................................................................................... 2
List of Tables .................................................................................................................................................................................. 4
List of Figures ................................................................................................................................................................................. 4
Section 1 - About the Company.......................................................................................................................................................... 5
Cytokinetics, Incorporated - Key Facts ............................................................................................................................................... 5
Cytokinetics, Incorporated - Key Employees ...................................................................................................................................... 6
Cytokinetics, Incorporated - Key Employee Biographies .................................................................................................................... 7
Cytokinetics, Incorporated - Major Products and Services ................................................................................................................. 8
Cytokinetics, Incorporated - Pharmaceutical Pipeline Products Data ................................................................................................. 9
Cytokinetics, Incorporated, Pipeline Products by Therapy Area ..................................................................................................... 9
Cytokinetics, Incorporated, Pipeline Products by Development Phase ......................................................................................... 10
Cytokinetics, Incorporated - History.................................................................................................................................................. 12
Cytokinetics, Incorporated - Company Statement ............................................................................................................................ 14
Cytokinetics, Incorporated - Locations And Subsidiaries .................................................................................................................. 15
Head Office ................................................................................................................................................................................... 15
Section 2 – Company Analysis ......................................................................................................................................................... 16
Cytokinetics, Incorporated - Business Description ........................................................................................................................... 16
Cytokinetics, Incorporated - Corporate Strategy............................................................................................................................... 17
Cytokinetics, Incorporated - SWOT Analysis .................................................................................................................................... 18
SWOT Analysis - Overview........................................................................................................................................................... 18
Cytokinetics, Incorporated - Strengths .......................................................................................................................................... 18
Strength - Patent Portfolio ......................................................................................................................................................... 18
Strength - Focused Research Activities .................................................................................................................................... 18
Strength - Partnership with Amgen............................................................................................................................................ 18
Cytokinetics, Incorporated - Weaknesses ..................................................................................................................................... 19
Weakness - Termination of Alliance with GlaxosmithKline ........................................................................................................ 19
Weakness - Weak Profitability Indicators .................................................................................................................................. 19
Cytokinetics, Incorporated - Opportunities .................................................................................................................................... 19
Opportunity - Orphan Drug Designation .................................................................................................................................... 19
Opportunity - Product Pipeline Portfolio .................................................................................................................................... 19
Opportunity - Growth Potential: Oncology ................................................................................................................................. 20
Opportunity - Demographic Trends ........................................................................................................................................... 20
Cytokinetics, Incorporated - Threats ............................................................................................................................................. 20
Threat - Competitive Landscape ............................................................................................................................................... 20
Threat - Uncertain Research and Development Activities ......................................................................................................... 20
Threat - Regulatory Environment .............................................................................................................................................. 21
Cytokinetics, Incorporated - Key Competitors .................................................................................................................................. 22
Section 3 – Company Financial Ratios ............................................................................................................................................. 23
Financial Ratios - Capital Market Ratios........................................................................................................................................... 23
Financial Ratios - Annual Ratios ...................................................................................................................................................... 23
Performance Chart ........................................................................................................................................................................... 25
Financial Performance...................................................................................................................................................................... 25
Financial Ratios - Interim Ratios....................................................................................................................................................... 26
Financial Ratios - Ratio Charts ......................................................................................................................................................... 27
Section 4 – Company’s Lifesciences Financial Deals and Alliances ................................................................................................ 28
Cytokinetics, Incorporated (CYTK) - Financial and Strategic SWOT Reference Code: GDPH66590FSA
Analysis Review
Source : www.globalcompanyintelligence.com Page 2
© GlobalData. This report is a licensed product and is not to be copied, reproduced, shared or resold in any form
Cytokinetics, Incorporated, Pharmaceuticals & Healthcare, Deals By Year, 2006 to YTD 2012................................................... 28
Cytokinetics, Incorporated, Pharmaceuticals & Healthcare, Deals By Type, 2006 to YTD 2012 .................................................. 29
Cytokinetics, Incorporated, Recent Deals Summary ........................................................................................................................ 30
Section 5 – Company’s Recent Developments ................................................................................................................................ 31
Cytokinetics, Incorporated, Recent Developments ....................................................................................................................... 31
Apr 26, 2012: Cytokinetics Reports Revenue Of $1.8m In Q1 2012 ......